At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 99 enrolled
Drug / intervention
Miebodrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease
In Brief
A Phase 4 clinical trial evaluating Miebo for Dry Eye. Completed, enrolled 99 participants across 7 sites.
Detailed Summary
An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20252026
Enrollment StartFeb 2024
First PostedMar 2024
Primary CompletionJun 2024
TodayJul 2026
First PostedMar 13, 2024
Enrollment StartFeb 28, 2024
Primary CompletionJun 17, 2024
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.3 years ago
Interventions
Miebodrug
Miebo® (perfluorohexyloctane ophthalmic solution) Dosage: one drop of MIEBO four times daily into each eye Dosage form: Ophthalmic solution: 100% perfluorohexyloctane. Frequency: 4 times daily for 14 days